维妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | CD20 |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 728917-18-8  |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6458H9918N1706O2026S46 |
| 摩尔质量 | 145,349.06 g·mol−1 |
维妥珠单抗（INN：veltuzumab；开发代号：IMMU-106[1]）是一种单克隆抗体（靶向CD20），正在研究用于治疗非霍奇金淋巴瘤。[2][3]截至2011年12月[update]，该药物正在进行I/II期临床试验。[4]当与米拉珠单抗一起使用时，它显示出活性。[5]
该药物由Immunomedics开发。
2015年8月，美国食品药品监督管理局授予其治疗免疫性血小板减少症的孤儿药地位。[6]II期试验计划将持续5年。[6]
参考资料
[编辑]- ^ Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491
. PMID 19710501. doi:10.1182/blood-2009-06-228890.
- ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ^ Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.
- ^ 6.0 6.1 FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015 [2024-04-18]. （原始内容存档于2019-09-07）.
